Ambu stock trades higher as sales outlook lifted after Q3 jump; trims FCF forecast

Published 22/08/2025, 08:26
© Reuters.

Investing.com -- Shares of Ambu A/S (CSE:AMBUb) rose on Friday after the Danish medical device maker posted higher third-quarter revenue, raised its full-year sales outlook and cut its cash flow forecast.

Ambu lifted its guidance for full-year organic revenue growth to 12-14%, up from 11-14%, and maintained its EBIT margin target of 13-15%. 

The company lowered its free cash flow assumption to about DKK 400 million from more than DKK 500 million. 

Free cash flow in the quarter came to DKK 128 million, down from DKK 163 million, while the nine-month total dropped to DKK 277 million from DKK 426 million.

Revenue for the quarter ended June 30 increased to DKK 1.51 billion from DKK 1.38 billion a year earlier, equal to 12% organic growth and 9% reported growth. 

Net profit fell to DKK 123 million from DKK 134 million, while earnings per share slipped to DKK 0.46 from DKK 0.50.

Operating profit before special items declined to DKK 170 million from DKK 178 million, with the EBIT margin narrowing to 11.3% from 12.9%. 

Gross margin dropped to 58.9% from 60.2%, weighed by foreign exchange effects and tariff costs. EBITDA before special items was DKK 263 million, compared with DKK 267 million.

By business line, Endoscopy Solutions rose 15.9% organically, with pulmonology up 11.2% and urology, ENT and gastroenterology up 20.8%. 

Anesthesia and Patient Monitoring grew 6.4% organically. Geographically, North America advanced 12.8%, Europe climbed 11.5% and Rest of World increased 7.9%.

For the first nine months of the fiscal year, revenue rose to DKK 4.57 billion from DKK 4 billion, with EBIT before special items increasing to DKK 637 million from DKK 498 million and the margin improving to 13.9% from 12.4%. Net profit was DKK 494 million, up from DKK 370 million a year earlier.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.